Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Sep 17, 2019 1:22pm
77 Views
Post# 30136180

RE:RE:RE:Benedict

RE:RE:RE:Benedict Long, emotions and fairy tales told by GUD MNGT helped you,  me  and others to keep missing the economic logic and metrics. I accept the fact that there may not be good deals in biotech for MA though I strongly doubt that because deal have been made every week. But wen you are holding 800 M in cash you have a fiduciary investment duty to investors to invest and get a safe return for the cash while waiting for good deals to come by if ever. Buffet does that. It is not that difficult to hire a money manager to manage the 800 M and get a return of a minimum of 5 to 6 percent per year on the cash. That would equate to 200 M earning for GUD over the past five Years. This one man show is economic amaturism, bs and idiocy. Why investors do not revolt is beyond me as it is simple economics. Though I have to accept that the smart investors have left long ago and waiting on the side line. I was not that smart. Rock is correct when he points out that GUD has become a heaven for short sellers by playing the up and down price spreads. Doe JG and MNGT care?  No............why should they as long as they keep getting cheap future options every Year as soon as the old ones expire. For them is a no loose game
Bullboard Posts